NCT02379663

Prophylaxis of Deep Vein Thrombosis Following Total Hip Arthroplasty

Efficacy and Safety for Prophylaxis of Deep Vein Thrombosis Following Total Hip Arthroplasty

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 639 (actual)
• Sponsor: Samsung Medical Center · Academic / Other
• Sex: All
• Age: 20 Years
• Healthy volunteers: Accepted

Summary

This prospective study compares an oral direct factor Xa inhibitor with LMWH for thromboprophylaxis in the patients undergoing THA.

Conditions

• Osteoarthritis, Hip
• Femur Head Necrosis
• Femoral Neck Fractures

Interventions

Type	Name	Description
DRUG	Rivaroxaban	Rivaroxaban was taken orally in a dosage of 10mg once daily
DRUG	Enoxaparin	Enoxaparin was injected subcutaneously in a dosage of 40mg once daily
OTHER	Normal saline	subcutaneous injection of 1 cc of normal saline once daily

Timeline

• Start date: 2012-01-01
• Primary completion: 2013-01-01
• Completion: 2013-01-01
• First posted: 2015-03-05
• Last updated: 2015-03-05